Targeting inflammation to treat diabetic kidney disease: the road to 2030

S Rayego-Mateos, RR Rodrigues-Diez… - Kidney international, 2023 - Elsevier
Diabetic kidney disease (DKD) is one of the fastest growing causes of chronic kidney
disease and associated morbidity and mortality. Preclinical research has demonstrated the …

Novel pharmacological interventions for diabetic kidney disease

SK Tan, JA Pinzon-Cortes… - Current Opinion in …, 2024 - journals.lww.com
Renal specific outcome trials have become more popular and are increasing the available
armamentarium to diminish the progression of renal decline in patients at greater risk of end …

[HTML][HTML] Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?

SK Tan, ME Cooper - Expert Opinion on Emerging Drugs, 2023 - Taylor & Francis
Seng Kiong Tan, Department of Diabetes, Central Clinical School, Monash University, Level
5, 99 Commercial Rd Melbourne, Melbourne, VIC 3004, Australia Diabetes Centre, Khoo …

[HTML][HTML] Recent advancements in targeted protein knockdown technologies—emerging paradigms for targeted therapy

M Joshi, P Dey, A De - Exploration of Targeted Anti-tumor Therapy, 2023 - ncbi.nlm.nih.gov
A generalized therapeutic strategy for various disease conditions, including cancer, is to
deplete or inactivate harmful protein targets. Various forms of protein or gene silencing …

Comparative Multi-omic Mapping of Human Pancreatic Islet Endoplasmic Reticulum and Cytokine Stress Responses Provides Insights into Type 2 Diabetes Genetics

EK Sokolowski, R Kursawe, V Selvam, RM Bhuiyan… - bioRxiv, 2024 - biorxiv.org
Endoplasmic reticulum (ER) and inflammatory stress responses are two pathophysiologic
factors contributing to islet dysfunction and failure in Type 2 Diabetes (T2D). However, how …